Literature DB >> 10462059

Discovery and characterization of endogenous cannabinoids.

B R Martin1, R Mechoulam, R K Razdan.   

Abstract

The characterization of cannabinoid receptors and signal transduction mechanisms provided the impetus for the searching for endogenous ligands for this system. The result was a family of fatty acid derivatives that interact with cannabinoid receptors to varying degrees. The two ligands that have received the most attention are anandamide (AN) and 2-arachidonolyl-glycerol (Ara-Gl). They are both present in central as well as peripheral tissues. Mechanisms for the synthesis and metabolism of AN have been described. Presently, the physiological stimuli for production and release of AN are unknown. As a result, elucidation of its physiological role remains elusive. However, it seems reasonable to conclude that both AN and 2-Ara-Gl interact with cannabinoid receptors in both peripheral and central tissue to produce a wide range of effects. Administration of these ligands to laboratory animals produce effects that are quite similar to those elicited by delta9-tetrahydrocannabinol (THC), the psychoactive constituent in marijuana. Nevertheless, there are some pharmacological differences between the plant-derived THC and the endogenous cannabinoids that could be due to either pharmadynamic or pharmacokinetics dissimilarities. Extensive structure-activity relationship studies have provided some vital insights into the actions of the endogenous ligands. First and foremost, systematic structural alterations in AN have additional support that it is acting at the cannabinoid receptors in a fashion similar to that of THC. Development of metabolically stable analogs of AN, as well as those with greater receptor affinity, have helped substantiate AN and THC similarities. Nevertheless, pharmacological differences remain between the endogenous and exogenous ligands. Whether these differences are due to the nature of their interaction with the cannabinoid receptors, activation of unique signaling pathways, interactions with non-cannabinoid receptors, or pharmacokinetic considerations remain to be resolved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462059     DOI: 10.1016/s0024-3205(99)00281-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  48 in total

Review 1.  How many endobains are there?

Authors:  G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Immunoactive cannabinoids: therapeutic prospects for marijuana constituents.

Authors:  S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 3.  Endocannabinoids and exercise.

Authors:  A Dietrich; W F McDaniel
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

4.  Endocannabinoids and their implications for epilepsy.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2004 Sep-Oct       Impact factor: 7.500

5.  Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase.

Authors:  F Anthony Romero; Wu Du; Inkyu Hwang; Thomas J Rayl; F Scott Kimball; Donmienne Leung; Heather S Hoover; Richard L Apodaca; J Guy Breitenbucher; Benjamin F Cravatt; Dale L Boger
Journal:  J Med Chem       Date:  2007-02-06       Impact factor: 7.446

Review 6.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

7.  Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues.

Authors:  Katerina Otrubova; Monica Brown; Michael S McCormick; Gye W Han; Scott T O'Neal; Benjamin F Cravatt; Raymond C Stevens; Aron H Lichtman; Dale L Boger
Journal:  J Am Chem Soc       Date:  2013-04-12       Impact factor: 15.419

8.  Novel, potent THC/anandamide (hybrid) analogs.

Authors:  Caryl Bourne; Sucharita Roy; Jenny L Wiley; Billy R Martin; Brian F Thomas; Anu Mahadevan; Raj K Razdan
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

9.  Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis.

Authors:  Susanne A Wolf; Anika Bick-Sander; Klaus Fabel; Perla Leal-Galicia; Svantje Tauber; Gerardo Ramirez-Rodriguez; Anke Müller; Andre Melnik; Tim P Waltinger; Oliver Ullrich; Gerd Kempermann
Journal:  Cell Commun Signal       Date:  2010-06-17       Impact factor: 5.712

10.  Biomarkers of endocannabinoid system activation in severe obesity.

Authors:  Jack C Sipe; T Michael Scott; Sarah Murray; Olivier Harismendy; Gabriel M Simon; Benjamin F Cravatt; Jill Waalen
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.